ABSTRACT

The ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly known as COVID-19, has presented an unprecedented challenge to public health systems worldwide. In this context, the Systemic Immuno-Inflammatory Index (SIII) emerges as a potential prognostic marker, offering insights into the dynamic balance between systemic inflammation and the host immune response. SIII, calculated as the product of the neutrophil count and the platelet-to-lymphocyte ratio, provides a comprehensive reflection of the immune and inflammatory milieu. This study aims to explore the utility of the Systemic Immuno-Inflammatory Index in the context of COVID-19, shedding light on its potential as a predictive tool for disease severity, progression, and overall prognosis. The study included 30 patients who applied to our hospital with respiratory tract infection complaints and who tested positive for SARS-CoV-2 as a result of the PCR test, and 35 patients who tested negative for PCR. Laboratory data were taken from hospital records. A total of  37 (56.9%) of the participants were male. The most common presenting complaints were cough (76.5%) and cough (67.5%). COVID-19 and control groups were similar in terms of average age (p=0.865). No significant difference was found between the groups in terms of mean SII value (p=0.768). In conclusion, the findings from our study show that the SII value cannot provide reliable data in distinguishing between COVID-19 and other upper respiratory tract infections.

Keywords

Systemic Immuno-Inflamatory Index, COVID-19, SARS-CoV-2.

MJE-002